Trexquant Investment LP Sells 157,097 Shares of Urogen Pharma $URGN

Key Points

• Trexquant Investment LP significantly reduced its stake in Urogen Pharma by 91.0%, selling 157,097 shares and leaving it with 15,454 shares valued at $171,000.
• Institutional investors collectively own 91.29% of Urogen Pharma, with several hedge funds increasing their positions in the company during the previous quarter.
• Urogen Pharma reported negative earnings of ($1.05) per share for the last quarter, missing estimates, while analysts have expressed mixed ratings and price targets ranging from $30.00 to $40.00 on the stock.

Trexquant Investment LP reduced its position in Urogen Pharma (NASDAQ:URGN - Free Report) by 91.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,454 shares of the company's stock after selling 157,097 shares during the period. Trexquant Investment LP's holdings in Urogen Pharma were worth $171,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of URGN. RTW Investments LP increased its holdings in Urogen Pharma by 1.3% during the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company's stock worth $40,841,000 after purchasing an additional 47,447 shares during the last quarter. Toronto Dominion Bank bought a new position in shares of Urogen Pharma in the fourth quarter worth $18,628,000. Vestal Point Capital LP boosted its stake in Urogen Pharma by 307.5% during the fourth quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company's stock valued at $17,360,000 after buying an additional 1,230,000 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Urogen Pharma by 2.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company's stock valued at $14,667,000 after purchasing an additional 36,084 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of Urogen Pharma by 14.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 786,472 shares of the company's stock valued at $8,698,000 after purchasing an additional 100,000 shares during the period. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Oppenheimer set a $31.00 price target on Urogen Pharma and gave the stock a "buy" rating in a research note on Friday, June 13th. HC Wainwright decreased their price objective on Urogen Pharma from $50.00 to $40.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Wall Street Zen raised Urogen Pharma from a "sell" rating to a "hold" rating in a report on Saturday. Guggenheim restated a "buy" rating and set a $30.00 target price (up previously from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. Finally, Piper Sandler began coverage on Urogen Pharma in a research report on Monday, August 18th. They issued an "overweight" rating and a $36.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, Urogen Pharma currently has an average rating of "Buy" and an average price target of $32.00.

Insider Transactions at Urogen Pharma

In other news, General Counsel Jason Drew Smith sold 7,522 shares of the business's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $19.14, for a total value of $143,971.08. Following the sale, the general counsel directly owned 41,492 shares in the company, valued at $794,156.88. The trade was a 15.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Mark Schoenberg sold 10,000 shares of the business's stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $17.69, for a total value of $176,900.00. Following the completion of the sale, the insider owned 148,229 shares in the company, valued at approximately $2,622,171.01. This trade represents a 6.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 25,062 shares of company stock valued at $465,115. Insiders own 4.70% of the company's stock.

Urogen Pharma Stock Up 0.1%

Shares of Urogen Pharma stock traded up $0.01 during trading on Tuesday, reaching $18.07. 1,329,367 shares of the company were exchanged, compared to its average volume of 1,126,295. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $21.71. The firm has a market capitalization of $835.92 million, a price-to-earnings ratio of -5.44 and a beta of 1.10. The business has a 50-day moving average price of $18.37 and a 200-day moving average price of $13.00.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.23). Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. The business had revenue of $24.22 million during the quarter, compared to analyst estimates of $23.06 million. On average, equities research analysts forecast that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.